SCHEMBL27218814

SCHEMBL27218814

Cc1cc(N)nc(SCCCc2nc(-c3ccc(Cl)cc3)no2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.55
▸ NPC1 O15118 2/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ HTT P42858 2/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ SIRT2 Q8IXJ6 3/20 0.52
▸ ALDH1A1 P00352 1/20 0.49
▸ CYP1A2 P05177 2/20 0.48
▸ NOTUM Q6P988 2/20 0.47
▸ TDP1 Q9NUW8 3/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ TSHR P16473 2/20 0.45
▸ HDAC2 Q92769 3/20 0.44
▸ HDAC1 Q13547 2/20 0.44
▸ HDAC8 Q9BY41 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ IDO1 P14902 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31494416 0.89 RAB9A (0.54) LMNANPC1RAB9AHTTSMN1; SMN2
SCHEMBL27218734 0.80 S1PR1 (0.46) LMNANPC1RAB9AHTTSMN1; SMN2
SCHEMBL27218848 0.76 SIRT2 (0.52) LMNANPC1RAB9AHTTSMN1; SMN2
SCHEMBL31494430 0.75 SMN1; SMN2 (0.72) LMNANPC1RAB9AHTTSMN1; SMN2
SCHEMBL27218936 0.75 RAB9A (0.71) LMNANPC1RAB9AHTTSMN1; SMN2
SCHEMBL27218886 0.74 SMN1; SMN2 (0.70) LMNANPC1RAB9AHTTSMN1; SMN2
SCHEMBL27218812 0.74 SIRT2 (0.52) LMNANPC1RAB9AHTTSMN1; SMN2
SCHEMBL27218874 0.74 HTT (0.69) LMNANPC1RAB9AHTTSMN1; SMN2
SCHEMBL29808136 0.71 TDP1 (0.50) NPC1RAB9ASMN1; SMN2ALDH1A1CYP1A2
SCHEMBL28869626 0.71 SIRT2 (0.75) LMNANPC1RAB9AHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 LMNA 3526/4885NPC1 781/4885RAB9A 2474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback